Tenecteplase for Acute Ischemic Stroke Thrombolysis: Practical Considerations and Real-World Implementation

Area of Science:

• Neurology
• Emergency Medicine
• Pharmacology

Background:

• Alteplase is the sole FDA-approved treatment for acute ischemic stroke (AIS).
• Tenecteplase, a newer fibrinolytic, is gaining traction due to clinical trial data, workflow efficiency, and cost benefits.
• The medical community is evaluating tenecteplase's role in AIS thrombolysis.

Purpose of the Study:

• To synthesize current evidence comparing tenecteplase and alteplase for AIS.
• To discuss the implications of off-label tenecteplase use.
• To outline practical considerations for transitioning from alteplase to tenecteplase.

Main Methods:

• Review of current clinical trial evidence.
• Discussion of institutional experience with tenecteplase.
• Analysis of treatment considerations, off-label use, consent, accreditation, and cost.
• Detailing workflow modifications for a safe transition.

Main Results:

• Evidence is being evaluated for tenecteplase's noninferiority or superiority to alteplase.
• Off-label use and its ramifications are under scrutiny.
• Practical aspects of transitioning stroke care protocols are detailed.

Conclusions:

• Tenecteplase presents a viable alternative to alteplase for AIS thrombolysis.
• Careful consideration of evidence, off-label use, and workflow integration is essential.
• Transitioning to tenecteplase requires strategic planning for safe and effective implementation.